Abstract | OBJECTIVE: METHOD: In this observational study, samples were collected from patients with venous leg ulcers (VLUs), patients with type 2 diabetes with neuropathic foot ulcers (DFUs), and from another cohort of VLU patients with sterile split-thickness skin graft donor sites after autologous skin grafting, serving as healing control wounds. MMP-9 and TIMP-1 concentrations were determined by enzyme-linked immunosorbent assays. MMP-9 and gelatinase activities were determined in wound fluids in subsets of the patients. RESULTS: A total of 24 patients took part in the study. No significant differences in MMP-9 wound fluid levels were found among the three groups. TIMP-1 levels were markedly and significantly lower in the two chronic wound groups resulting in a severely unbalanced MMP-9/TIMP-1 ratio, especially notable in the VLU group and possibly in the elevated endogenous MMP-9 activity (p<0.01) compared with the acute wound fluids. At least 20% of the chronic wound fluids displayed atypical patterns on gelatin zymography and showed high general gelatinase activity that was not inhibited by either TIMP-1 or by a gelatinase inhibitor ( AG3340). MMP-9 levels were higher in the sera of the patients with type 2 diabetes. CONCLUSION: We hypothesise that non- MMP proteinases contribute to matrix destruction in a significant number of chronic wounds. Blocking the excessive MMP-9 activity may be insufficient to normalise wound healing. The reasons and effects of the very low TIMP-1 levels in chronic wounds need further clarification.
|
Authors | Hannah Trøstrup, Per Holstein, Tonny Karlsmark, Claus Moser, Magnus S Ågren |
Journal | Journal of wound care
(J Wound Care)
Vol. 27
Issue 11
Pg. 724-734
(11 02 2018)
ISSN: 0969-0700 [Print] England |
PMID | 30398935
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- TIMP1 protein, human
- Tissue Inhibitor of Metalloproteinase-1
- Gelatin
- Matrix Metalloproteinase 9
|
Topics |
- Aged
- Aged, 80 and over
- Chronic Disease
- Diabetes Mellitus, Type 2
(complications)
- Diabetic Foot
(metabolism, physiopathology)
- Exudates and Transudates
(chemistry)
- Female
- Gelatin
(metabolism)
- Humans
- Male
- Matrix Metalloproteinase 9
(blood)
- Middle Aged
- Tissue Inhibitor of Metalloproteinase-1
(blood)
- Varicose Ulcer
(metabolism, physiopathology)
|